Invivyd Publication Validates Variant-Agnostic Antibody Protection Model
Event summary
- Invivyd published a peer-reviewed analysis in *Infectious Diseases and Therapy* demonstrating a statistical model correlating antibody levels to clinical protection from COVID-19 variants.
- The model, derived from data from the CANOPY Phase 3 clinical trial of pemivibart, aligns with prior Invivyd and external analyses.
- The analysis suggests clinical efficacy can be predicted from stable epitope drugging, independent of SARS-CoV-2 variation.
- PEMGARDA (pemivibart), an investigational monoclonal antibody, has received emergency use authorization from the FDA for pre-exposure prophylaxis.
The big picture
Invivyd’s findings challenge the conventional approach to COVID-19 antibody development, which often relies on extensive clinical trials for each variant. The ability to predict efficacy based on laboratory measurements could significantly streamline the development process and potentially broaden access to effective treatments. However, the model's reliance on stable epitopes highlights the ongoing risk of viral evolution rendering current antibodies ineffective.
What we're watching
- Regulatory Impact
- The potential for this correlate of protection model to accelerate regulatory pathways for Invivyd’s antibodies, reducing reliance on traditional animal models and lengthy trials, warrants close observation.
- Variant Landscape
- The continued emergence of SARS-CoV-2 variants with reduced susceptibility to pemivibart will test the model’s predictive power and potentially limit its utility, requiring ongoing monitoring of variant frequencies.
- Market Adoption
- The extent to which healthcare professionals and policymakers adopt this model for clinical decision-making and public health stewardship will determine the long-term commercial success of Invivyd’s antibody platform.
